AOD-9604 has an unusually well-documented clinical history for a research compound. It was taken through human trials — including a placebo-controlled Phase 2b study — by a company pursuing it as an obesity treatment. The trial did not meet its primary weight-loss endpoint against placebo.

What the Compound Actually Is

AOD-9604 is a fragment of human growth hormone corresponding to a region researchers theorized was responsible for growth hormone’s fat-metabolizing effects, without the region responsible for growth-promoting effects.

“The trial already asked the question the marketing is asking again — and got a different answer.”

— from this newsletter’s review of the compound’s public clinical trial record

The Trial That Didn’t Meet Its Endpoint

The Phase 2b trial tested AOD-9604 against placebo for weight loss in a large study population. It did not demonstrate statistically significant weight loss over placebo. The company discontinued the obesity program afterward.

How a Failed Trial Became a Research-Compound Listing

The same molecule that missed a placebo-controlled primary endpoint is frequently described in retail listings using language that implies established effectiveness, without reference to the trial that already tested that specific claim.